Starling Oncology, Inc.
STLN Nasdaq
SEC CIK 1799191
Follow Starling Oncology
Weekly email: filings, results
Revenue, last quarter
$169.8M
+24.3% vs same quarter last year
Net income
−$15.7M
+4.6% vs same quarter last year
EPS, diluted
−$0.13
+7.1% vs same quarter last year
Operating cash flow
$10.1M
+180.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $502.7M | - |
| FY24 | $393.4M | - |
| FY23 | $324.2M | −$83.1M |
| FY22 | $252.5M | $152K |
| FY21 | $203M | −$10.9M |
| FY20 | $187.5M | −$14.3M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −7.2% | - |
| FY24 | −15.3% | - |
| FY23 | −23.8% | −25.6% |
| FY22 | −32.5% | 0.1% |
| FY21 | −22.6% | −5.4% |
| FY20 | −4.4% | −7.6% |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$27.8M |
| FY24 | −$30.3M |
| FY23 | −$40.9M |
| FY22 | −$67.3M |
| FY21 | −$35.5M |
| FY20 | −$686K |
| FY19 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | $0 |
| FY23 | $1M |
| FY22 | $9M |
| FY21 | $0 |
| FY20 | - |
| FY19 | - |
- Starling Oncology
- Healthcare median
Show the numbers
| Year | Starling Oncology | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | −25.6% | −58% |
| FY22 | 0.1% | −80.4% |
| FY21 | −5.4% | −71.9% |
| FY20 | −7.6% | −62.2% |
| FY19 | - | −46.3% |